CAJ | 학술논문

目的分析生存期大于5年多发性骨髓瘤(MM)患者的临床特点及其与预后的关系.方法收集2005年9月至2009年9月确诊的43例生存期大于5年MM患者的临床资料,总结患者临床特征、实验室指标和治疗情况,并分析其与生存期的关系.结果 43例患者中,男性23例,女性20例,中位年龄59岁,中位生存期80个月,不同的国际ISS分期对应的中位生存期分别为Ⅰ期120个月,Ⅱ期93个月,Ⅲ期80个月.所有患者均接受过硼替佐米化疗;复发患者接受了含硼替佐米方案、DECP方案、来那度胺、三氧化二砷及脂质体多柔比星等药物治疗.化疗中位疗程数25个(15 ～ 46个).结论 MM的预后不仅与肿瘤负荷、宿主因素及肿瘤生物学特征等有关,还与治疗方案及对治疗的反应密切相关.硼替佐米、来那度胺等新型靶向药物对初诊及复发难治MM均有较好疗效.
목적 분석생존기대우5년다발성골수류(MM)환자적림상특점급기여예후적관계.방법 수집2005년9월지2009년9월학진적43례생존기대우5년MM환자적림상자료,총결환자림상특정、실험실지표화치료정황,병분석기여생존기적관계.결과 43례환자중,남성23례,녀성20례,중위년령59세,중위생존기80개월,불동적국제ISS분기대응적중위생존기분별위Ⅰ기120개월,Ⅱ기93개월,Ⅲ기80개월.소유환자균접수과붕체좌미화료;복발환자접수료함붕체좌미방안、DECP방안、래나도알、삼양화이신급지질체다유비성등약물치료.화료중위료정수25개(15 ～ 46개).결론 MM적예후불부여종류부하、숙주인소급종류생물학특정등유관,환여치료방안급대치료적반응밀절상관.붕체좌미、래나도알등신형파향약물대초진급복발난치MM균유교호료효.
Objective To analysis the relationship of clinical characteristics and prognosis of multiple myeloma (MM) patients surviving more than 5 years.Methods The clinical features, laboratory parameters and treatment programs of 43 cases diagnosed MM from September 2005 to September 2009 were collected to analyze the influence factors related to survival.Results 43 patients included 23 male cases, 20 female cases, with a median age of 59 years old (38-76 years old), and the median survival time was 80 months (60-124 months).Different ISS stage corresponded to different median survival phase, phase Ⅰ 120 months, phase Ⅱ 93 months, phase Ⅲ 80 months.The 43 patients had received the median of 25 cycles (15-46 cycles) of chemotherapy, all of them had received chemotherapy of bortezomib.The relapsed MM patients had received chemotherapy with bortezomib mainly, DECP, lenalidomide, arsenic trioxide and pcgylated liposomal doxorubicin.Conclusions Besides tumor burden, host factors and tumor biology, the prognosis of MM correlates with the treatment modality and response to therapy.The new target drugs such as bortezomib and lenalidomide have good curative effect on either newly diagnosed or relapsed and refractory MM.